Pulmozyme and Rash erythematous - a phase IV clinical study of FDA data

Summary:

Rash erythematous is reported as a side effect among people who take Pulmozyme (dornase alfa), especially for people who are female, 10-19 old, also take Creon, and have Sinusitis.

The phase IV clinical study analyzes which people have Rash erythematous when taking Pulmozyme. It is created by eHealthMe based on reports of 19,995 people who have side effects when taking Pulmozyme from the FDA, and is updated regularly.

What is Pulmozyme?

Pulmozyme has active ingredients of dornase alfa. It is often used in cystic fibrosis. eHealthMe is studying from 20,012 Pulmozyme users. Check the latest studies of Pulmozyme.

What is Rash erythematous?

Rash erythematous (redness of the skin) is found to be associated with 1,808 drugs and 1,905 conditions by eHealthMe. Check the latest studies of Rash erythematous.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

19,995 people reported to have side effects when taking Pulmozyme.
Among them, 49 people (0.25%) have Rash erythematous.

Could Pulmozyme cause Rash erythematous?

Among these 49 people:

What is the gender of people who have Rash erythematous when taking Pulmozyme? *

female: 59.18 %
male: 40.82 %

What is the age of people who have Rash erythematous when taking Pulmozyme? *

What are other drugs people take besides Pulmozyme? *

What are other side effects people have besides Rash erythematous? *

Weight Increased: 14 people, 28.57%
Productive Cough: 13 people, 26.53%
Oedema Peripheral (superficial swelling): 11 people, 22.45%
High Blood Pressure: 10 people, 20.41%
Nausea (feeling of having an urge to vomit): 10 people, 20.41%
Headache (pain in head): 9 people, 18.37%
Face Oedema (swelling of face): 8 people, 16.33%
Diarrhea: 7 people, 14.29%
Pain: 6 people, 12.24%
Gastrointestinal Sounds Abnormal: 6 people, 12.24%

What are the existing conditions these people have? *

Sinusitis (inflammation of sinus): 6 people, 12.24%
Headache (pain in head): 4 people, 8.16%
Lower Respiratory Tract Infection: 3 people, 6.12%
Rashes (redness): 2 people, 4.08%
Face Oedema (swelling of face): 2 people, 4.08%
Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 1 person, 2.04%
Infective Pulmonary Exacerbation Of Cystic Fibrosis (severe infective lung disease with production of abnormally thick mucus): 1 person, 2.04%
Haemolytic Anaemia (anaemia due to haemolysis): 1 person, 2.04%

* Approximation only. Some reports may have incomplete information.

Do you take Pulmozyme and have Rash erythematous?

- Check whether Rash erythematous is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Pulmozyme:

Pulmozyme (20,012 reports)

Browse all side effects of Pulmozyme:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rash erythematous:

Rash erythematous (1,808 drugs)

Browse all the conditions that are associated with Rash erythematous:

Rash erythematous (1,905 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dornase alfa (the active ingredients of Pulmozyme) and Pulmozyme (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.